Evidence map›Paper›PMID 26181333›Full record

ArticlePLoS pathogens2015

Lv4 Is a Capsid-Specific Antiviral Activity in Human Blood Cells That Restricts Viruses of the SIVMAC/SIVSM/HIV-2 Lineage Prior to Integration.

Massimo Pizzato, Sean Matthew McCauley, Martha R Neagu, Thomas Pertel, Claudia Firrito, Serena Ziglio, Ann Dauphin, Madeleine Zufferey, Lionel Berthoux, Jeremy Luban

Abstract read
In one paragraph

Article in PLoS pathogens, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. CypA is a molecular barrier to HIV emergence from Eastern chimpanzees.bioRxiv : the preprint server for biology · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. S2 from equine infectious anemia virus is an infectivity factor which counteracts the retroviral inhibitors SERINC5 and SERINC3.Proceedings of the National Academy of Sciences of the United States of America · 2016
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Massimo PizzatoDepartment of Microbiology and Molecular Medicine, University of Geneva, Geneva, Switzerland; Center for Integrative Biology, University of Trento, Trento, Italy.
Sean Matthew McCauleyProgram in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.
Martha R NeaguDepartment of Microbiology and Molecular Medicine, University of Geneva, Geneva, Switzerland.
Thomas PertelDepartment of Microbiology and Molecular Medicine, University of Geneva, Geneva, Switzerland.
Claudia FirritoDepartment of Microbiology and Molecular Medicine, University of Geneva, Geneva, Switzerland.
Serena ZiglioCenter for Integrative Biology, University of Trento, Trento, Italy.
Ann DauphinProgram in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.
Madeleine ZuffereyDepartment of Microbiology and Molecular Medicine, University of Geneva, Geneva, Switzerland.
Lionel BerthouxLaboratory of Retrovirology, University of Québec, Trois-Rivières, Quebec, Canada.
Jeremy LubanDepartment of Microbiology and Molecular Medicine, University of Geneva, Geneva, Switzerland; Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.

Funding

Human Genes that Influence HIV-1 Replication, Pathogenesis, and Immunity in IVDUsDP1DA034990 · NIDA · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI LUBAN, JEREMY · 2012 to 2016
$4.1M
Cyclophilin A Function in the Immune SystemR01AI059159 · NIAID · UNIVERSITY OF GENEVA · PI LUBAN, JEREMY · 2006 to 2011
$1.4M
Canadian Institutes of Health Research 102712NIAID NIH HHS R01 AI059159NIAID NIH HHS R01AI59159NIDA NIH HHS DP1 DA034990NIDA NIH HHS DP1DA034990
6 · The paper itself

Abstract

HIV-2 and SIVMAC are AIDS-causing, zoonotic lentiviruses that jumped to humans and rhesus macaques, respectively, from SIVSM-bearing sooty mangabey monkeys. Cross-species transmission events such as these sometimes necessitate virus adaptation to species-specific, host restriction factors such as TRIM5. Here, a new human restriction activity is described that blocks viruses of the SIVSM/SIVMAC/HIV-2 lineage. Human T, B, and myeloid cell lines, peripheral blood mononuclear cells and dendritic cells were 4 to >100-fold less transducible by VSV G-pseudotyped SIVMAC, HIV-2, or SIVSM than by HIV-1. In contrast, transduction of six epithelial cell lines was equivalent to that by HIV-1. Substitution of HIV-1 CA with the SIVMAC or HIV-2 CA was sufficient to reduce HIV-1 transduction to the level of the respective vectors. Among such CA chimeras there was a general trend such that CAs from epidemic HIV-2 Group A and B isolates were the most infectious on human T cells, CA from a 1° sooty mangabey isolate was the least infectious, and non-epidemic HIV-2 Group D, E, F, and G CAs were in the middle. The CA-specific decrease in infectivity was observed with either HIV-1, HIV-2, ecotropic MLV, or ALV Env pseudotypes, indicating that it was independent of the virus entry pathway. As2O3, a drug that suppresses TRIM5-mediated restriction, increased human blood cell transduction by SIVMAC but not by HIV-1. Nonetheless, elimination of TRIM5 restriction activity did not rescue SIVMAC transduction. Also, in contrast to TRIM5-mediated restriction, the SIVMAC CA-specific block occurred after completion of reverse transcription and the formation of 2-LTR circles, but before establishment of the provirus. Transduction efficiency in heterokaryons generated by fusing epithelial cells with T cells resembled that in the T cells, indicative of a dominant-acting SIVMAC restriction activity in the latter. These results suggest that the nucleus of human blood cells possesses a restriction factor specific for the CA of HIV-2/SIVMAC/SIVSM and that cross-species transmission of SIVSM to human T cells necessitated adaptation of HIV-2 to this putative restriction factor.

Indexed as

AnimalsAntiviral AgentsCapsidCell LineDendritic CellsHIV-2HumansLeukocytes, MononuclearSimian Immunodeficiency VirusT-LymphocytesVirus IntegrationAntiviral Agents

Identifiers

PMID26181333
PMCPMC4504712

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.